Drug conjugates with albumin and transferrin

Bibliography

• MAEDA H, WU J, SAWA T, MATSUMURA Y, HORI, K Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. Control. Release (2000) 65:271–284.
   PubMed Web of Science ®Google Scholar
• MAEDA H, MATSUMURA Y: Tumouritropic and lymphotropic principles of macromolecular prodrugs. Grit. Rev Titer. Drug Carrier Sys. (1989) 6:193–210.
   PubMed Web of Science ®Google Scholar
• SEYMOUR LW: Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev Then Drug Carrier Sys. (1992) 9:135–187.
   PubMed Web of Science ®Google Scholar
• DUNCAN R, SPREAFICO F: Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pliannacokinet. (1994) 27:290–306.
   PubMed Web of Science ®Google Scholar
• MATSUMURA Y, MAEDA H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins of the antitumour agent smancs. Cancer Res. (1986) 46:6387–6392.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules across tumour vasculature. Cancer Metast. Rev (1987) 6:559–593.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules in the tumour interstitium: a review. Cancer Res. (1987) 47:3039–3051.
   PubMed Web of Science ®Google Scholar
• YUAN F, DEILIAN M, FUKUMURA D et al.: Vascular permeability in a human tumour xenograft: molecular size dependence and cutoff size. Cancer Res. (1995) 55:3752–3756.
   PubMed Web of Science ®Google Scholar
• SINN H, SCHRENK HH, FRIEDRICH A, SCHILLING U, MAIER-BORST W: Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part 1. Nucl. Med. Biol. Int. I Rad. Appl. Instrum. (1990) 17:819–827.
   Google Scholar
• STEHLE G, SINN H, WUNDER A et al.: Plasma protein (albumin) catabolism by the tumour itself - implications for tumour metabolism and the genesis of cachexia. Grit. Rev Oncol Hematol. (1997) 26:77–100.
   PubMed Web of Science ®Google Scholar
• WUNDER A, STEHLE G, SINN H et al:Enhanced albumin uptake by rat tumours. bt.j Oncol (1997) 11:497–507.
   Google Scholar
• TANAKA T, KANEO Y, SHIRAMOTO S, IGUCHI S: The disposition of serum proteins as drug carriers in mice bearing sarcoma 180. Biol. Pliann. Bull. (1997) 16:1270–1275.
   Google Scholar
• AULBERT E: Transferrinmangelandmie bei malignen Tumourerkrankungen. Georg Thieme Verlag (Ed.) Stuttgart, Germany (1986).
   Google Scholar
• BROCK JH: Transferrins. In: Metalloproteins, Part 2: Metal Proteins with Non -redoxRoles PM Harrison (Ed.), Verlag Chemie, Weinheim, (1985):183–263.
   Google Scholar
• SUTHERLAND R, DELIA D, SCHNEIDER C, NEWMANN R, KEMSHEAD J, GREAVES M: Ubiquitous cell-surface glycoprotein on tumour cells is proliferation-associated receptor for transferrin. Proc. Nati Acad. Sci. USA (1980) 78:4515–4519.
   Web of Science ®Google Scholar
• TROWBRIDGE IS, OMARY MB: Human cell surface glycoprotein related to the cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. USA (1981) 78:3039–3043.
   PubMed Web of Science ®Google Scholar
• WAGNER E, CURIEL D, COTTEN M: Delivery of drugs, proteins and genes into cells using transferrin as ligand for receptor-mediated endocytosis. Adv. Drug Del. Rev (1994) 14:113–135.
   Web of Science ®Google Scholar
• KRATZ F, BEYER U: Serum proteins as drug carriers of anticancer agents, a review. Drug Delivery (1998) 5:1–19.
   Google Scholar
• COX MC, BARNHAM KJ, FRENKIEL TA et al.: Identification of platination sites on human serum transferrin using 13C and 15N NMR spectroscopy." Biol. haorg. Chem. (1999) 4:621–631.
   Google Scholar
• ELLIOTT RL, STJERNHOLM R, ELLIOTT MC: Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer. Cancer Detect. Prey. (1988) 12:469–480.
   PubMedGoogle Scholar
• FAULK WP, TAYLOR CG, YEH CJ, MCINTYRE JA: Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Mol. Biother. (1990) 2:57–60.
   PubMedGoogle Scholar
• STEHLE G, SINN H, WUNDER A et al.: The loading rate determines tumour targeting of methotrexate-albumin conjugates in rats. Anticancer Drugs (1997) 8:677–685.
   PubMed Web of Science ®Google Scholar
• WUNDER A, STEHLE G, SCHRENK HH et al.: Antitumour activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. hat. J Cancer. (1998) 76:884–890.
   PubMedGoogle Scholar
• STEHLE G, WUNDER A, SCHRENK HH, HARTUNG G, HEENE DL, SINN H: Methotrexate-albumin conjugate causes tumour growth delay in Dunning R3327 HI prostate cancer bearing rats. Anticancer Drugs (1999) 10:405–411.
   PubMedGoogle Scholar
• HARTUNG G, STEHLE G, SINN H et al.: Phase I-trial of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients. Lim J. Cancer (1997) 33:S249–250.
   Google Scholar
• HARTUNG G, STEHLE G, SINN H et al.: Phase I trial of methotrexate-albumin in a weekly iv. bolus regimen in cancer patients. Gin. Cancer Res. (1999) 5:753–759.
   PubMed Web of Science ®Google Scholar
• FIUME L, DI STEFANO G, BUSI C et al.: Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor.' Virol. Hepat. (1997) 4:363–370.
   PubMed Web of Science ®Google Scholar
• HOLMES DL, THIBAUDEAU K, ARCHEVEQUE B, MILENER PG, EZRIN AM, BRIDON DP: Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjugate Chem. (2000) 11:439–44.
   PubMed Web of Science ®Google Scholar
• KRATZ F, BEYER U, SCHOTTE MT: Polymer drug conjugates containing acid-cleavable bonds. Crit. Rev Ther. Drug Carrier Sys. (1999) 16:245–288.
   PubMed Web of Science ®Google Scholar
• KRATZ F, MOLLER-DRIVER R, HOFMANN I, DREVS J, UNGER C: A Novel Macromolecular Prodrug Concept Exploiting Endogenous Serum Albumin as a Drug Carrier for Cancer Chemotherapy.' Med. Chem. (2000) 43:1253–1256.
   Google Scholar
• KRATZ F, DREVS J, ESSER N, FICHTNER I, UNGER C: Superior in vivo efficacy of acid-sensitive doxorubicin derivatives with specific albumin-binding properties compared to the parent compound. Proc. Amer. Assoc. Cancer Res. (2001) 42\(Supp1.138):745.
   Google Scholar
• KRATZ F, DREVS J, BING G et al.: Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Biorg. Med. Chem. Lett. (2001) 11:2001–2006.
   PubMed Web of Science ®Google Scholar
• KRATZ F, FICHTNER I, ROTH T, FIEBIG HH, UNGER C: Amitumour activity of acid-sensitive transferrin and albumin doxorubicin conjugates in in vitro and in vivo human tumour xenograft models.' Drug Target. (2000) 8:305–318.
   PubMed Web of Science ®Google Scholar
• GABAY C, KUSHER I: Mechanisms of Disease: Acute-Phase proteins and other systemic responses to inflammation. N Engl. J. Med. (1999) 340:448–454.
   PubMed Web of Science ®Google Scholar
• BISTRIAN BR: Some practical and theoretic concepts in the nutritional assessment of the cancer patient. Cancer (1986) 58:1863–1866.
   PubMed Web of Science ®Google Scholar
• Conjuchem, Inc. Homepage: http:// www.conjuchem.com.
   Google Scholar